Peptides for Hair Growth — The Complete Guide

Growth Factors · Collagen Synthesis · Anti-Inflammatory

GHK-Cu (glycine-histidine-lysine-copper) is the best-characterized peptide for hair growth. It binds to follicle cells and stimulates production of key growth factors — including VEGF, KGF, and IGF-1 — essential for maintaining follicles in the anagen (active growth) phase. GHK-Cu also promotes collagen synthesis in the dermal papilla, activates proteasome activity to clear damaged proteins in follicle cells, and has demonstrated anti-inflammatory activity that reduces scalp-level inflammation contributing to follicle regression. Published research shows GHK-Cu increases follicle size, enhances hair shaft thickness, and stimulates new follicle development.

Vasodilation · Anagen Phase · Scalp Microcirculation

Minoxidil is the most clinically established topical hair loss treatment with decades of evidence. Its mechanism operates through potassium channel opening in vascular smooth muscle — dilating scalp microvasculature to increase blood flow and nutrient delivery to follicles. It also directly extends the anagen (growth) phase by upregulating prostaglandin E2 and other follicle-stimulating signals. Compounded formulations combine Minoxidil with Finasteride, Ketoconazole, Azelaic acid, and Tretinoin in a single topical solution rather than requiring separate applications.

DHT Blockade · Follicle Protection · Androgenetic Alopecia

DHT is the primary driver of androgenetic alopecia. Produced from testosterone via 5-alpha reductase in hair follicles, DHT progressively shortens the anagen phase and miniaturizes follicles until the hair shaft becomes vellus and eventually ceases production. Finasteride blocks 5-AR Type II, reducing scalp DHT by up to 70% with oral dosing. Topical Finasteride (in compounded Minoxidil solutions) provides scalp-level DHT reduction with significantly lower systemic absorption. Azelaic acid and Ketoconazole in multi-agent formulas provide additional 5-AR inhibition and anti-inflammatory activity.

Angiogenesis · VEGF · Tissue Repair

BPC-157 has emerging data in scalp and follicle health through its primary mechanism of angiogenesis — stimulating formation of new blood vessels at treatment sites. Hair follicles are among the most metabolically active structures in the body and are highly sensitive to blood flow. BPC-157 upregulates VEGF and other angiogenic growth factors, improving the microvascular supply to follicles. It also has systemic anti-inflammatory properties that may reduce chronic scalp inflammation associated with androgenetic alopecia. Best understood as a supporting protocol alongside GHK-Cu or Minoxidil-based primary protocols.

• Stimulates key follicle growth factors — VEGF, KGF, IGF-1
• Increases anagen phase duration — extends active hair growth cycle
• Promotes dermal papilla collagen synthesis for thicker hair shafts
• Anti-inflammatory at the follicle and scalp level
• Published data shows increased follicle size and hair shaft diameter
• Works on both scalp and follicle — systemic and local effects

• Combines the two most established hair loss interventions in a single daily application
• Minoxidil 5% extends anagen phase and improves scalp vascularity
• Finasteride 0.1% topical reduces scalp DHT with lower systemic exposure than oral
• Single solution simplifies compliance versus separate products
• Appropriate for both male and female pattern hair loss
• Topical Finasteride avoids most systemic side effects associated with oral dosing

• Tretinoin increases Minoxidil dermal penetration and local bioavailability
• Enhanced efficacy compared to Minoxidil alone at the same concentration
• Tretinoin's retinoid activity supports scalp skin cell turnover and follicle health
• Appropriate for patients with scalp buildup or skin that limits topical absorption
• No systemic DHT effect — preferred for patients not requiring Finasteride
• Compatible with GHK-Cu copper peptide topicals as part of a layered protocol

Most Comprehensive Topical Protocol

• Most comprehensive single-formula DHT-blocking and growth-stimulating protocol
• Minoxidil 5% — anagen extension and scalp vasodilation
• Finasteride 0.1% — topical 5-AR Type II inhibition
• Azelaic acid 12.5% — 5-AR inhibitor and anti-androgenic activity via a second pathway
• Ketoconazole 2% — anti-fungal, anti-inflammatory, and independent DHT-blocking activity
• Four mechanisms in one application — maximum synergy with single-formula compliance

• Most clinically studied oral DHT-blocking protocol for male pattern hair loss
• Reduces systemic DHT by up to 70% with once-daily dosing
• Established efficacy in halting progression and stimulating regrowth
• Oral systemic action complements topical Minoxidil protocols
• Compounded tablets at significantly lower cost than branded Propecia
• 30ct and 90ct quantities available for cost-effective ongoing therapy

• Systemic GHK-Cu delivery — reaches follicles via bloodstream, not just scalp surface
• Activates over 4,000 repair and regeneration genes including follicle-relevant growth factors
• Promotes nerve growth factor and VEGF systemically
• Supports skin and scalp collagen quality body-wide
• Complements topical GHK-Cu for dual-route copper peptide delivery
• Anti-inflammatory systemically — reduces chronic inflammation suppressing follicle cycling

• Stimulates VEGF-driven angiogenesis — improves scalp blood vessel density and flow
• Upregulates growth factors at injection sites for local follicle support
• Systemic anti-inflammatory properties reduce chronic scalp inflammation
• Oral form provides systemic availability without injection
• Complements GHK-Cu and Minoxidil protocols at the vascular level
• Supports overall tissue repair and regenerative capacity

DHT-driven follicle miniaturization is the most common cause of hair loss. DHT reduction is the foundation, with Minoxidil for anagen extension.

Diffuse thinning without a clear androgenetic pattern is often driven by declining follicle growth factor signaling, poor scalp vascularity, or chronic inflammation. GHK-Cu and Minoxidil are the appropriate foundation.

Patients with significant DHT-driven progression benefit from the most comprehensive topical DHT-blocking protocol alongside GHK-Cu regeneration support.

Weeks 1–8

Establishing the Protocol

Most patients experience initial increased shedding during weeks 2–6 of starting a Minoxidil-based protocol — this is a well-documented phenomenon where the drug pushes resting telogen hairs into the growth phase, temporarily displacing old hairs before new growth appears. This is a positive sign. GHK-Cu begins stimulating follicle growth factor expression. Finasteride begins reducing scalp DHT levels within the first 2 weeks.

Months 2–4

Early Regrowth & Stabilization

New hair growth begins to appear in areas with viable follicles. Progressive reduction in daily shed count is typically noticeable by month 3 for patients on DHT-blocking protocols. GHK-Cu effects on hair shaft thickness begin to become apparent. Patients often describe hair feeling 'fuller' or 'denser' before visible length changes are apparent.

Month 4–12

Active Regrowth Phase

The most significant cosmetic improvements become apparent between months 4 and 12 of consistent protocol adherence. Published data on Minoxidil/Finasteride combination protocols shows measurable hair density improvement in 80–90% of male patients and 60–70% of female patients at 12 months. GHK-Cu data shows continued improvement in follicle size and hair shaft diameter with ongoing use. Maintenance requires ongoing protocol adherence.

GHK-Cu Hair Restoration Formula — 30g

Copper peptide scalp formula. Follicle growth factor stimulation and scalp tissue repair.

GHK-Cu Injectable — 5mL

Systemic copper peptide delivery. Complements topical GHK-Cu for dual-route follicle support.

Minoxidil 5% / Finasteride 0.1% — 60mL

Two-agent topical. Anagen extension + topical DHT reduction. Primary for androgenetic alopecia.

Minoxidil 5% / Tretinoin 0.025% — 60mL

Enhanced Minoxidil absorption via Tretinoin. For non-androgenetic or adjunct use.

Minoxidil 5% / Azelaic / Finasteride / Ketoconazole — 60mL

Four-agent formula. Maximum topical DHT blockade. For moderate to advanced alopecia.

Finasteride 1mg Tablets — 30ct

Oral systemic DHT reduction. Most established oral protocol for males. 90ct also available.

BPC-157 — 5mL Injectable

Scalp angiogenesis support. VEGF-driven follicle microvasculature improvement.

Identify Your Hair Loss Pattern

Is your hair loss following a pattern (temples, crown, hairline) — suggesting androgenetic alopecia? Or is it diffuse overall thinning? This determines whether DHT reduction or follicle growth factor stimulation is the higher-priority mechanism. If unsure, your provider will assess during consultation.

Complete Your Async Provider Consultation

Answer a brief health intake questionnaire at your own pace — no video call, no waiting room. A licensed provider reviews your submission, confirms the appropriate protocol and formulation, and issues your prescription when clinically appropriate.

Receive Your Order

Your prescription is filled by Optimal Balance Pharmacy — a licensed compounding pharmacy — and shipped via FedEx Standard Overnight to your door.

Commit to the Timeline

Hair growth cycles operate on a 3–6 month timeframe. Consistent daily application through the initial shed phase (weeks 2–6 with Minoxidil) is essential. Most patients see meaningful improvement between months 4 and 12. Follow-up consultations allow protocol adjustments as your response develops.